Novo Nordisk, a leading healthcare company and a world leader in diabetes care, has highlighted the importance of insulin treatment in relation to management of diabetes.

The company is developing new strategies that aim to change the pattern of diabetes treatment management. This is done through a multi-pronged approach involving healthcare professional training, awareness campaigns, patient education and training of other medical personnel involved in the diabetes management, it said.

The company last week brought together 430 diabetes specialists and doctors from more than 18 countries at the Premix Summit in Dubai to discuss and review treatment guidelines and the diabetes pandemic, both regionally and a on a global scale.

Premix insulin is an extremely effective way to control patients’ sugar levels after eating a meal, it said.

In addition, the Premix Summit highlighted the epidemics of global obesity and type 2 diabetes as well as the latest clinical data; examine the importance of postprandial glucose (PPG) control in the treatment of diabetes; and discuss the value of and barriers to early insulin initiation as well as intensification.

This IDF Congress in Dubai next month will issue new guidelines on diabetes treatment and these guidelines are produced in order to help doctors manage diabetes in all its stages.

The new guidelines will give recommendations on how to treat diabetes step-by-step.

Mads Bo Larsen, vice president, Africa, Gulf and India, Novo Nordisk, said: “There is a clear need to further educate the general public about the human, social and economic drama of diabetes and its complications. We believe that awareness combined with prevention, early detection, better disease management and education can make a significant difference, both in terms of people living longer and healthier lives and to maintain a strong workforce.” – TradeArabia News Service